Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: The effect of riluzole treatment

Clinical Neurology and Neurosurgery

Volumn 110, Issue 3, 2008, Pages 222-226

  Andreadou, Elisabeth ^a   Kapaki, Elisabeth ^a   Kokotis, Panagiotis ^a   Paraskevas, George P ^a   Katsaros, Nikolaos ^a   Libitaki, Georgia ^a   Zis, Vassilios ^a   Sfagos, Constantinos ^a   Vassilopoulos, Demetrios ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Amyotrophic lateral sclerosis (ALS); Glutamate (glu); Glycine (gly); Plasma; Riluzole

Indexed keywords

GLUTAMIC ACID; GLYCINE; RILUZOLE;

ADULT; AGED; AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; FEMALE; HUMAN; MALE; NERVE CELL EXCITABILITY; NEUROTRANSMISSION; PATHOGENESIS; SURVIVAL; TREATMENT RESPONSE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; FEMALE; GLUTAMIC ACID; GLYCINE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RILUZOLE; SEX CHARACTERISTICS;

EID: 39749169193     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2007.10.018     Document Type: Article

References (31)

1. Plaitakis A., and Caroscio J.T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 22 (1987) 575-579
2. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 28 (1990) 3-8
3. Iłżecka J., and Stelmasiak Z. Serum bilirubin concentration in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 105 (2003) 237-240
4. Van Den Bosch L., Van Damme P., Bogaert E., and Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 1762 (2006) 1068-1082
5. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., and Kuncl R.W. Selective loss of glial glutamate transport GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38 (1995) 73-84
6. Appel S.H. Excitotoxic neuronal death in amyotrophic lateral sclerosis. Trends Neurosci 16 (1993) 3-5
7. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Eng J Med 330 (1994) 585-591
8. Traynor B.J., Alexander M., Corr B., Frost E., and Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis. A population based study in Ireland, 1996-2000. J Neurol 250 (2003) 473-479
9. World Federation of Neurology Research Group on Neuromuscular Disease. The El Escorial Criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(Suppl.):96-107.
10. Appel V., Stewart S.S., Smith G., and Appel S.H. A rating scale of amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 22 (1987) 328-333
11. Dagilas A., Kimiskidis V., Aggelopoulou M., Kapaki E., Fitili C., Libitaki G., Papagiannopoulos S., Kazis D., Kazis A., and Aidonis A. Changes in blood neurotransmitter and steroid levels during evoked vertigo. Otol Neurootol 26 (2005) 476-480
12. Paraskevas G.P., Triantafyllou N.I., Kapaki E., Limpitaki G., Petropoulou O., and Vassilopoulos D. Add-on lamotrigine treatment and plasma glutamate levels in epilepsy: relation to treatment response. Epilepsy Res 70 (2006) 184-189
13. European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of Metabolism (http://www.erndimqa.nl).
14. Iwasaki Y., Ikeda K., and Kinoshita M. Plasma aminoacid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci 107 (1992) 219-222
15. Camu W., Billiard M., and Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 88 (1993) 51-55
16. Niebroj-Dobosz I., and Janik P. Amino acids acting as neurotransmitters in amyotrophic lateral sclerosis (ALS). Acta Neurol Scand 100 (1999) 6-11
17. Spreux-Varoquaux O., Bensimon G., Lacomblez L., Salachas F., Pradat P.F., Le Forestier N., et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 193 (2002) 73-78
18. Van Westerlaak M.G.H., Joosten E.A.J., Grinau A.A.M., Cools A.R., and Bär P.R. Differential cortico-motoneuron vulnerability after chronic mitochondrial inhibition in vitro and the role of glutamate receptors. Brain Res 922 (2001) 243-249
19. Gredal O., Pakkenberg B., and Nielsen M. Muscarinic N-methyl-D-aspartate(NMDA)and benzodiazepine receptor binding sites in cortical membranes from amyotrophic lateral sclerosis patients. J Neurol Sci 143 (1996) 121-125
20. Nakamura R., Kamakura K., and Kwak S. Late-onset selective neuronal damage in the rat spinal cord induced by continuous intrathecal administration of AMPA. Brain Res 654 (1994) 279-285
21. Cudkowicz M.E., McKenna-Yasek D., Sapp E., Chin W., Geller B., Hayden DL, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 41 (1997) 210-221
22. Iłżecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. Clin Neurol Neurosurg 106 (2004) 289-293
23. Niebroj-Dobosz I., Janik P., and Kwieciński H. Effect of riluzole on serum aminoacids in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 106 (2002) 39-43
24. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 47 Suppl 4 (1996) S233-41
25. Azbill R.D., Mu X., and Springer J.E. Riluzole increases high affinity glutamate uptake in rat spinal cord synaptosomes. Brain Research 871 (2000) 175-180
26. ΜcLean M.J. Principles of neuropharmacology and therapeutics. In: Bradley W.G., Daroff R.B., Fenichel G.M., and Jankovic J. (Eds). Neurology in clinical practice. fourth ed. (2004), Butterworth Heinemann, Philadelphia 881-884
27. Robberecht W.L., and Vianney De Jong J.M.B. Oxidative stress in amyotrophic lateral sclerosis: pathogenic mechanism or epiphenomenon?. In: Brown Jr. B., Meininger V., and Swash M. (Eds). Amyotrophic lateral sclerosis (2000), M Dunitz, London 211-222
28. Sendtner M. Neurotrophic factors. In: Brown Jr. B., Meininger V., and Swash M. (Eds). Amyotrophiclateral sclerosis (2000), M Dunitz, London 289-308
29. Pasinelli P., and Brown Jr. R.H. Apoptosis in amyotrophic lateral sclerosis: a review. In: Brown Jr. B., Meininger V., and Swash M. (Eds). Amyotrophic lateral sclerosis (2000), M Dunitz, London 363-376
30. Hebert T., Drapeau P., Pradier L., and Dunn R.J. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 45 (1994) 1055-1060
31. Kalra S., Arnold D.L., and Cashman N.R. Biological markers in the diagnosis and treatment of ALS. J Neurol Sci 165 (1999) S27-S32